Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia

Lazaros Lekakis, Marcos de Lima

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

Acute myeloid leukemia (AML) is a hematologic malignancy with a peak incidence over the age of 55 years. AML of older patients is less curable with conventional chemotherapy, and, when it relapses, is almost uniformly fatal. Novel treatments hold the promise of improving the results of therapy, but have failed so far to show dramatic change in the prognosis. Allogeneic stem cell transplantation using traditional myeloablative preparative regimens is not easily tolerated by the elderly and/or frailer patient, and may lead to prohibitive treatment-related mortality rates. Most patients treated in the past were younger and devoid of comorbid clinical conditions. Novel reduced-intensity regimens made allogeneic transplants applicable to the elderly, providing the benefit of the graft-versus-leukemia effect to a larger number of patients in need. Here we review the indications for allogeneic transplants in AML and discuss reduced-intensity conditioning regimens.

Original languageEnglish (US)
Pages (from-to)785-798
Number of pages14
JournalExpert review of anticancer therapy
Volume8
Issue number5
DOIs
StatePublished - Aug 29 2008
Externally publishedYes

Keywords

  • Acute myeloid leukemia
  • Altogeneic stem cell transplantation
  • Nonmyetoablative
  • Reduted-intensity conditioning

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this